Attività Prestazioni Didattica Corsi Eventi Bandi Contatti
Istituto > Pubblicazioni > Anno 2009
Pubblicazioni Istituto inserite in PubMed e nell'Osservatorio della Ricerca - Anno 2009

Santucci MA, Corradi V, Mancini M, Manetti F, Radi M,Schenone S, Botta M C6-unsubstitutedpyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective againstimatinib mesylate resistant chronic myeloid leukemia cell lines Chem Med Chem. 2009 Jan;4(1):118-26

Morra E, Barosi G, Bosi A, Ferrara F, Locatelli F, Marchetti M, Martinelli G, Mecucci C, Vignetti M, Tura S. Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation Haematologica. 2009 Jan;94(1):102-12

Cortes JE, Baccarani M, Guilhot F, Druker BJ,Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B,Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T,Kantarjian HM, Radich JP, Hughes TP PhaseIII, randomized, open-label study of daily imatinib mesylate 400 mg versus800 mg in patients with newly diagnosed, previously untreated chronic myeloidleukemia in chronic phase using molecular end points: tyrosine kinaseinhibitor optimization and se J Clin Oncol, 2010 Jan 20;28(3):424-30

Palandri F, Testoni N, Luatti S, Marzocchi G, BaldazziC, Stacchini M, Castagnetti F, Breccia M, Specchia G, Pane F, Saglio G,Martinelli G, Baccarani M, Rosti G Influence of additional cytogeneticabnormalities on the response and survival in late chronic phase chronicmyeloid leukemia patients treated with imatinib: long-term results Leuk Lymphoma. 2009 Jan;50(1):114-8

Arpinati M, Chirumbolo G, Nicolini B, Agostinelli C,Rondelli D Selective apoptosis of monocytes andmonocyte-derived DCs induced by bortezomib (Velcade) Bone Marrow Transplant. 2009 Feb;43(3):253-9

Palandri F, Iacobucci I, Soverini S, Castagnetti F,Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M,Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G,Baccarani M, Rosti G Treatment of Philadelphia-positivechronic myeloid leukemia with imatinib: importance of a stable Clin Cancer Res. 2009 Feb 1;15(3):1059-63

Patriarca F, Petrucci MT, Bringhen S, Baldini L,Caravita T, Corradini P, Corso A, Di Raimondo F, Falcone A, Ferrara F,Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P,Vacca A, Cavo M, Boccadoro Considerations in the treatment ofmultiple myeloma: a consensus statement from Italian experts Eur J Haematol. 2009 Feb;82(2):93-105

Baruzzi A, Iacobucci I, Soverini S, Lowell CA,Martinelli G, Berton G c-Abl and Src-family kinasescross-talk in regulation of myeloid cell migration FEBS Lett, 2009 Nov 11

Palandri F, Castagnetti F, Alimena G, Testoni N,Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, LevatoL, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G,Baccarani M, Rosti G The long-term durability ofcytogenetic responses in patients with accelerated phase chronic myeloidleukemia treated with imatinib 600 mg: the GIMEMA CML Working Partyexperience after a 7-year follow-up Haematologica. 2009 Feb;94(2):205-12

Follo MY, Finelli C, Clissa C, Mongiorgi S, Bosi C,Martinelli G, Baccarani M, Manzoli L, Martelli AM, Cocco L Phosphoinositide-phospholipase C beta1mono-allelic deletion is associated with myelodysplastic syndromes evolutioninto acute myeloid leukemia J Clin Oncol. 2009 Feb 10;27(5):782-90

Palandri F, Ottaviani E, Salmi F, Catani L, PolverelliN, Fiacchini M, Martinelli G, Baccarani M, Vianelli N JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response totherapy and long-term outcome in a cohort of 275 patients Leuk Lymphoma. 2009 Feb;50(2):247-53

Dispenzieri A, Kyle R, Merlini G,Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S,Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M,Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G,Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma Leukemia. 2009 Feb;23(2):215-24

Walz C, Score J, Mix J, Cilloni D,Roche-Lestienne C, Yeh RF, Wiemels JL, Ottaviani E, Erben P, Hochhaus A,Baccarani M, Grimwade D, Preudhomme C, Apperley J, Martinelli G, Saglio G,Cross NC, Reiter A; European The molecular anatomy of the FIP1L1-PDGFRAfusion gene Leukemia. 2009 Feb;23(2):271-8

Corrado P, Mancini M, Brusa G, Petta S, Martinelli G, Barbieri E, Santucci MA. Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia. Leukemia. 2009 Feb;23(2):405-6.

Martinelli G, Soverini S, Iacobucci I, Baccarani M Intermittent targeting as a tool tominimize toxicity of tyrosine kinase inhibitor therapy Nat Clin Pract Oncol. 2009 Feb;6(2):68-9

Curti A, Trabanelli S, Salvestrini V, Baccarani M,Lemoli RM The role of indoleamine2,3-dioxygenase in the induction of immune tolerance: focus on hematology Blood. 2009 Mar 12;113(11):2394-401

Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S, Sacchi N, Sormani MP, Fanin R, Bandini G, Bonifazi F, Bosi A, Rambaldi A, Alessandrino PE, Falda M, Bacigalupo A. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transpl 2009 Apr 13

Lemoli RM, D’ Addio A, Marotta G, Pezzullo L, Zuffa E, Montanari M, De Vivo A, Bonini A, Galieni P, Carella AM, Guidi S, Michieli M, Olivieri A, Bosi A.. Busulphan/Melphalan and Autologous Stem Cell Transplantation in AML patients in first CR: a “Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” retrospective study. Bone Marrow Transpl, 2009 Oct 5

Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Filì C, Lucchi P, Malagola M, Bergonzi C, Roccaro A, Peli A, Ricotta D,Caimi L, Fanin R, Baccarani M, Russo D Kineticsof Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT:results of a Bone Marrow Transplant, 2009 Dec;44(11):729-37

Fenaux P, Mufti GJ, Hellstrom-LindbergE, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, ListA, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L,McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDSSu Efficacy of azacitidine compared withthat of conventional care regimens in the treatment of higher- riskmyelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol. 2009 Mar;10(3):223-32

Palandri F, Derenzini E, Ottaviani E, Polverelli N,Catani L, Salmi F, Sabattini E, Bacci F, Zinzani PL, Baccarani Association of essentialthrombocythemia and non-Hodgkin lymphoma: a single-centre experience Leuk Lymphoma. 2009 Mar;50(3):481-4

Cavrini F, Stanzani M, Liguori G, Sambri V Identification of an invasive infection of R.oryzae in a haematologica l patientusing a molecular technique Mycoses. 2009 Mar 17

Palandri F, Catani L, Testoni N, Ottaviani E,Polverelli N, Fiacchini M, De Vivo A, Salmi F, Lucchesi A, Baccarani Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductivetherapy Am J Hematol. 2009 Apr;84(4):215-20

Suzumiya J, Ohshima K, Tamura K,Karube K, Uike N, Tobinai K, Gascoyne RD, Vose JM, Armitage JO, WeisenburgerDD; International Peripheral T-Cell Lymphoma Project The International Prognostic Indexpredicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of126 patients from the International Peripheral T-Cell Lymphoma Project Ann Oncol 2009 Apr;20(4):715-21

Au WY,Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J,Armitage JO, Liang R; International Peripheral T-Cell Lymphoma Project Clinical differences between nasal andextranasal natural killer/T-cell lymphoma: a study of 136 cases from theInternational Peripheral T-Cell Lymphoma Project Blood 2009 Apr 23;113(17):3931-7

Castagnetti F, Palandri F, Amabile M,Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G,Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G,Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party Results of high-dose imatinib mesylatein intermediate Sokal risk chronic myeloid leukemia patients in early chronicphase: a phase 2 trial of the GIMEMA CML Working Party Blood. 2009 Apr 9;113(15):3428-34

Brusamolino E, Bacigalupo A, Barosi G, Biti G, GobbiPG, Levis A, Marchetti M, Santoro A, Zinzani PL, Tura S Classical Hodgkin's lymphoma inadults: guidelines of the Italian Society of Hematology, the Italian Societyof Experimental Hematology, and the Italian Group for Bone MarrowTransplantation on initial work-up, management, Haematologica. 2009 Apr;94(4):550-65

Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G,Castellucci P, Marchi E, Fina M, Ambrosini V, Pellegrini C, Alinari L,Derenzini E, Montini G, Broccoli A, Bacci F, Pileri S, Baccarani M Role of [18F]fluorodeoxyglucosepositron emission tomography scan in the follow-up of lymphoma J Clin Oncol. 2009 Apr 10;27(11):1781-7

Baccarani M,. New directions in the treatment ofpatients with chronic myeloid leukemia: introduction Semin Hematol. 2009 Apr;46(2 Suppl 3):S1-4 Baccarani M, Dreyling M; ESMOGuidelines Working Group Chronic myelogenous leukemia: ESMOclinical recommendations for diagnosis, treatment and follow-up Ann Oncol. 2009 May;20 Suppl 4:105-7

Baccarani M, Rosti G, Castagnetti F,Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth- HansenH, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U,Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G Comparison of imatinib 400 mg and 800mg daily in the front-line treatment of high-risk, Philadelphia- positivechronic myeloid leukemia: a European LeukemiaNet Study Blood. 2009 May 7;113(19):4497-504

Varani S, Stanzani M, Paolucci M, Melchionda F,Castellani G, Nardi L, Landini MP, Baccarani M, Pession A, Diagnosis of bloodstream infections inimmunocompromised patients by real-time PCR J Infect. 2009 May;58(5):346-51

Breccia M, Palandri F, Iori AP, Colaci E, Latagliata R,Castagnetti F, Torelli GF, Usai S, Valle V, Martinelli G, Rosti G, Foà R,Baccarani M, Alimena G Second-generation tyrosine kinaseinhibitors before allogeneic stem cell transplantation in patients withchronic myeloid leukemia resistant to imatinib Leukemia Res. 2009 May 28

Catani L, Zini R, Sollazzo D, Ottaviani E, VannucchiAM, Ferrari S, Baccarani M, Vianelli N, Lemoli RM, Molecular profile of CD34+stem/progenitor cells according to JAK2V617F mutation status in Leukemia. 2009 May;23(5):997-1000

Pagano L, Valentini CG, Posteraro B, Girmenia C, OssiC, Pan A, Candoni A, Nosari A, Riva M, Cattaneo C, Rossini F, Fianchi L,Caira M, Sanguinetti M, Gesu GP, Lombardi G, Vianelli N, Stanzani M, MironeE, Pinsi G, Facchetti F, Manca N, Savi L, Mettimano M Zygomycosis in Italy: a survey of FIMUA-ECMM(Federazione Italiana di Micopatologia Umana ed Animale and EuropeanConfederation of Medical Mycology) J Chemotherapy. 2009 Jun;21(3):322-9

Malagola M, Baccarani M, Russo D Leukemia and multi-drug resistance:too many mechanisms of drug resistance or too many doctors resistant? Leuk Lymphoma. 2009 Jun;50(6):1058-60

Mancini M, Veljkovic N, Corradi V, Zuffa E, Corrado P,Pagnotta E, Martinelli G, Barbieri E, Santucci MA 14-3-3 ligand prevents nuclear importof c-ABL protein in chronic myeloid leukemia Traffic. 2009 Jun;10(6):637-47

De Stefano V, Za T, Rossi E, VannucchiAM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Vianelli N,Guglielmelli P, Pieri L, Scognamiglio F, Cacciola E, Rodeghiero F, PoglianiEM, Finazzi G, Gugliotta L, Leone G, Barbui T; for the GIMEMA Chro Increased risk of recurrent thrombosisin patients with essential thrombocythemia carrying the homozygous JAK2 V617Fmutation Ann Hematol. 2009 Jul 7

Potenza L, Volzone F, Riva G, Soverini S, Martinelli S,Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E,Maccaferri M, Baccarani M, Martinelli G, Torelli G, Luppi M Interferon-alpha may restoresensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positiveacute lymphoblastic leukaemia with F317L mutation Br J Haematol. 2009 Jul;146(2):227-30

Santucci MA, Mancini M, Corradi V, Lacobucci I,Martinelli G, Botta M, Schenone S New SRC/ABL inhibitors for chronicmyeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells Invest New Drugs. 2009 Jul 24

Mancini M, Corradi V, Petta S, Martinelli G, BarbieriE, Santucci MA mTOR inhibitor RAD001 (Everolimus)enhances the effects of imatinib in chronic myeloid leukemia by raising thenuclear expression of c-ABL protein Leukemia Res. 2009 Jul 28

Piccaluga PP, Sabattini E, Bacci F, Agostinelli C, Righi S, Salmi F, Testoni N, Paolini S, Castagnetti F, Martinelli G, Falini B, Pileri SA Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia Leukemia. 2009 Jul;23(7):1370-1

Terpos E, Sezer O, Croucher PI,García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M,Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P; EuropeanMyeloma Network The use of bisphosphonates inmultiple myeloma: recommendations of an expert panel on behalf of theEuropean Myeloma Network Ann Oncol. 2009 Aug;20(8):1303-17

Kumar S, Giralt S, Stadtmauer EA,Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N,Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S,Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H,Richardson Mobilization in myeloma revisited:IMWG consensus perspectives on stem cell collection following initial therapywith thalidomide-, lenalidomide-, or bortezomib-containing regimens Blood. 2009 Aug 27;114(9):1729-35

Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ FIGHT-AML-301 Investigators. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood. 2009 Aug 6;114(6):1166-73.

Voso MT, Santini V, Finelli C, Musto P, Pogliani E,Angelucci E, Fioritoni G, Alimena G, Maurillo L, Cortelezzi A, Buccisano F,Gobbi M, Borin L, Di Tucci A, Zini G, Petti MC, Martinelli G, Fabiani E, FaziP, Vignetti M, Piciocchi A, Liso V, Amadori S, Leo Valproic acid at therapeutic plasmalevels may increase 5-azacytidine efficacy in higher risk Clin Cancer Res. 2009 Aug 1;15(15):5002-7

Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Müschen M Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009 Aug 3;206(8):1739-53

Martinelli G, Iacobucci I, Papayannidis C, Soverini S. New targets for Ph+ leukaemia therapy. Best Pract Res Clin Haematol. 2009 Sep;22(3):445-54

Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A,Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L,Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M,Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Bac Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene ina large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients Blood. 2009 Sep 3;114(10):2159-67

Soverini S, Gnani A, Colarossi S, Castagnetti F,Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A,Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M,Cilloni D, Rosti G, Baccarani Philadelphia-positive patients whoalready harbor imatinib-resistant Bcr-Abl kinase domain mutations have ahigher likelihood of developing additional mutations associated withresistance to second- or third-line tyrosine kinase Blood. 2009 Sep 3;114(10):2168-71

Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009 Sep 8;16(3):232-45.

Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S,Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM,Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML,Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Per Systemic cardiac amyloidoses: diseaseprofiles and clinical courses of the 3 main types Circulation. 2009 Sep 29;120(13):1203-12

Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M,Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G,Papayannidis C, Paolini S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G,Pane F, Baccarani M, Foà R IKZF1 (Ikaros) Deletions inBCR-ABL1-Positive Acute Lymphoblastic Leukemia Are Associated With ShortDisease- Free Survival and High Rate of Cumulative Incidence of Relapse: AGIMEMA AL WP Report J Clin Oncol. 2009 Sep 21

Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in J Clin Oncol. 2009 Sept 1;27(25):4204-10

Iacobucci I, Lonetti A, Messa F, Ferrari A, Cilloni D,Soverini S, Paoloni F, Arruga F, Ottaviani E, Chiaretti S, Messina M,Vignetti M, Papayannidis C, Vitale A, Pane F, Piccaluga PP, Paolini S, BertonG, Baruzzi A, Saglio G, Baccarani M, Foà R, Martinelli Different isoforms of the B-cellmutator activation-induced cytidine deaminase are aberrantly expressed inBCR- ABL1-positive acute lymphoblastic leukemia patients Leukemia. 2009 Sep 17

Perrone G, Hideshima T, Ikeda H, OkawaY, Calabrese E, Gorgun G, Santo L, Cirstea D, Raje N, Chauhan D, Baccarani M,Cavo M, Anderson KC Ascorbic acid inhibits antitumoractivity of bortezomib in vivo Leukemia. 2009 Sep;23(9):1679-86

Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C,Testoni N, Chiarini F, Ramazzotti G, Baccarani M, Martelli AM, Manzoli L,Martinelli G, Cocco L Reduction ofphosphoinositide-phospholipase C beta1 methylation predicts theresponsiveness to azacitidine in Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16811-6

Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, Rabascio C, Rossi L, Martin-Padura I, Castagnetti F, Marighetti P, Martinelli G, Baccarani M, Ferrari S, Manfredini Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resi stance to imatinib. Blood, 2009 Oct 23

Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study Clin Lymphoma Myeloma. 2009 Oct;9(5):381-5

Crea F, Giovannetti E, Zinzani PL, Danesi R Pharmacologic rationale for earlyG-CSF prophylaxis in cancer patients and role of pharmacogenetics intreatment optimization Crit Rev Oncol Hematol 2009 Oct;72(1):21-44

Blalock WL, Grimaldi C, Fala F, Follo M, Horn S, Basecke J, Martinelli G, Cocco L, Martelli AM PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation J Cell Physiol. 2009 Oct;221(1):232-41.

Cavo M, Di Raimondo F, Zamagni E, Patriarca F,Tacchetti P, Casulli AF, Volpe S, Perrone G, Ledda A, Ceccolini M, CalifanoC, Bigazzi C, Offidani M, Stefani P, Ballerini F, Fiacchini M, de Vivo A,Brioli A, Tosi P, Baccarani M Short-term thalidomide incorporatedinto double autologous stem-cell transplantation improves outcomes incomparison with double autotransplantation for multiple myeloma J Clin Oncol. 2009 Oct 20;27(30):5001-7

Cavo M, Pantani L, Tacchetti P, Pallotti MC, Brioli A, Petrucci A, Zamagni E, Tosi P. Thalidomide Maintenance in Multuple Myeloma: Certainties and Contrversies. J Clin Oncol. 2009 Oct 5

Stefoni V, Broccoli A, Pellegrini C, Derenzini E, FinaM, Zinzani PL CNS recurrence of primary mediastinallarge b-cell lymphoma after complete remission J Neuro-Oncol. 2009 Oct;95(1):135-9

Grever MR, Zinzani PL Long-term follow-up studies in hairycell leukemia Leuk Lymphoma 2009 Oct;50 Suppl 1:23-6

Palumbo A, Sezer O, Kyle R, Miguel JS,Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, KumarS, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, DaviesF, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, R International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible forstandard high-dose chemotherapy with autologous stem cell transplantation Leukemia. 2009 Oct;23(10):1716-30

Giralt S, Stadtmauer EA, HarousseauJL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A,Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J,Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, International myeloma working group(IMWG) consensus statement and guidelines regarding the current status ofstem cell collection and high-dose therapy for multiple myeloma and the roleof plerixafor (AMD 3100) Leukemia. 2009 Oct;23(10):1904-12

Zinzani PL, Venturini F,Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, ArgnaniL, Quirini F, Pileri S, Baccarani M Gemcitabine as single agent inpretreated T-cell lymphoma patients: evaluation of the long-term outcome Ann Oncol, 2009 Nov 3

Maffione AM, Castellucci P, Stefoni V, Nanni C, Tani M, Rubello D, Ambrosini V, Zinzani PL, Franchi R, Fanti S. Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. Clin Nucl Med. 2009 Nov;34(11):777-8

Morabito F, Gentile M, Ciolli S, Petrucci MT,Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, Palmieri S,Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, DiRaimondo F, Boccadoro M, Palumbo A, Cavo M SAFETY AND EFFICACY OFBORTEZOMIB-BASED REGIMENS FOR MULTIPLE MYELOMA PATIENTS WITH RENALIMPAIRMENT: A RETROSPECTIVE STUDY OF ITALIAN MYELOMA NETWORK GIMEMA Eur J Haematol, 2009 Nov 23

Cavo M, Pantani L, Tacchetti P, Pallotti MC, Brioli A,Petrucci A, Zamagni E, Tosi P Thalidomide maintenance in multiple myeloma:certainties and controversies J Clin Oncol, 2009 Nov 10;27(32):e186-7; author re

Derenzini E, Stefoni V, Pellegrini C, Fina MP, BroccoliA, Venturini F, Gandolfi L, Pileri SA, Martelli M, Petti MC, Perrotti A, DeRenzo A, Zaja F, Baccarani M, Zinzani PL Cyclophosphamide,doxorubicin, vincristine, methotrexate, bleomicin and prednisone plusrituximab in untreated young patients with low-risk (age-adjustedinternational prognostic index 0-1) diffuse large B-cell lymphoma Leuk Lymphoma, 2009 Nov;50(11):1824-9

Papayannidis C, Derenzini E, Iacobucci I, Curti A,Paolini S, Cilloni D, Baccarani M, Martinelli G Successfulcombination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicinin adult refractory B- acute lymphoblastic leukemia Am JHematol, 2009 Dec;84(12):849-50

Martinelli G, Ryan G, Seymour JF,Nassi L, Steffanoni S, Alietti A, Calabrese L, Pruneri G, Santoro L,Kuper- Hommel M, Tsang R, Zinzani PL, Taghian A, Zucca E, Cavalli F Primary follicular and marginal-zonelymphoma of the breast: clinical features, prognostic factors and outcome: astudy by the International Extranodal Lymphoma Study Group Ann Oncol, 2009 Dec;20(12):1993-9

Nicolini FE, Mauro MJ, Martinelli G, Kim DW, SoveriniS, Müller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH, Apperley JF, YagasakiF, Pearson JD, Peter S, Sanz Rodriguez C, Preudhomme C, Giles F, Goldman JM,Zhou W Epidemiologic study on survival of chronic myeloidleukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315Imutation Blood, 2009 Dec 17;114(26):5271-8

Rosti G, Palandri F, Castagnetti F, Breccia M, LevatoL, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR,Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N,Martinelli G, Alimena G, Pane F, Saglio G, Baccarani Nilotinib for the frontline treatmentof Ph(+) chronic myeloid leukemia Blood, 2009 Dec 3;114(24):4933-8

Testoni N, Marzocchi G, Luatti S, Amabile M, BaldazziC, Stacchini M, Nanni M, Rege-Cambrin G, Giugliano E, Giussani U, AbruzzeseE, Kerim S, Grimoldi MG, Gozzetti A, Crescenzi B, Carcassi C, Bernasconi P,Cuneo A, Albano F, Fugazza G, Zaccaria A, Martinell Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situhybridization and chromosome banding analysis for the definition of completecytogenetic response: a study of theGIMEMA CML WP Blood, 2009 Dec 3;114(24):4939-43

Palandri F, Castagnetti F, Soverini S, Poerio A,Gugliotta G, Luatti S, Amabile M, Martinelli G, Rosti G, Baccarani M Pancreatic enzyme elevation in chronicmyeloid leukemia patients treated with nilotinib after imatinib failure Haematologica, 2009 Dec;94(12):1758-61

Baccarani M, Cortes J, Pane F, Niederwieser D, SaglioG, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A,Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, SilverRT, Goldman J, Hehlmann R; European LeukemiaNet Chronicmyeloid leukemia: an update of concepts and management recommendations ofEuropean LeukemiaNet J Clin Oncol, 2009 Dec 10;27(35):6041-51

Baccarani M, Cortes J, Pane F, Niederwieser D, SaglioG, Apperley J, Cervantes F,Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T,Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman Chronic myeloid leukemia: an update ofconcepts and management recommendations of European LeukemiaNet J ClinOncol, 2009 Dec 10;27(35):6041-51

Domenicali M, Caraceni P,Giannone F, Baldassarre M, Lucchetti G, Quarta C, Patti C, Catani L, Nanni C,Lemoli RM, Bernardi M A novel model of CCl4-induced cirrhosiswith ascites in the mouse J Hepatol, 2009 Dec;51(6):991-9

Baldazzi C, Luatti S, Marzocchi G, Stacchini M,Gamberini C, Castagnetti F, Palandri F, Rosti G, Baccarani M, Emergence of clonal chromosomalabnormalities in Philadelphia negative hematopoiesis in chronic myeloidleukemia patients treated with nilotinib after failure of imatinib therapy Leukemia Res. 2009 Dec;33(12):e218-20



 
Istituto di Ematologia "Lorenzo e Ariosto Seràgnoli" - Via Massarenti, 9 - 40138 Bologna - Tel. +39 051 636 3680 Fax +39 051 636 4037